Insight

Aradhana Kasimsetty: Denise Sabatino and I present a review of the known risks of AAV vector-mediated liver cancer

Photo collage of Aradhana Kasimsetty and Denise Sabatino

Apr 21, 2024, 18:27

Aradhana Kasimsetty: Denise Sabatino and I present a review of the known risks of AAV vector-mediated liver cancer

Aradhana Kasimsetty, , shared on LinkedIn:

“With the recent FDA guidances on gene therapy products, risk management and concerns of vector-derived malignancies are at the forefront of clinical development.

As part of the special issue “Liver Directed Adeno‐Associated Virus Gene Therapy”, Denise Sabatino and I present a review of the known risks of AAV vector-mediated liver cancer and how integration site monitoring synergizes with routine patient care after liver-directed gene therapy.

Integration and the risk of liver cancer—Is there a real risk?”

Additional information.
Source: Aradhana Kasimsetty/LinkedIn

Adeno‐Associated Virus Gene Therapy Aradhana Kasimsetty cancer Denise Sabatino FDA gene therapy liver cancer OncoDaily Oncology Perelman School of Medicine

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage